

Trading in subscription rights and BTAs in Acarix' rights issue will commence tomorrow

Press release

Malmö, 9 October 2019

Trading in subscription rights and BTAs in Acarix' rights issue has been delayed, due to late submission of the application to Nasdaq.

This situation is beyond Acarix control.

Trading will commence tomorrow, October 10. All other information in the press release about Acarix rights issue, published earlier today is confirmed as accurate.

Adjusted timetable for the Rights Issue

Subscription period in the Rights Issue	9 – 25 October 2019
Trading in subscription rights	10 – 23 October 2019
Trading in BTAs	10 October 2019 – around week 47, 2019
Announcement of the outcome of the Rights Issue	Around 29 October 2019

Contact persons for further information

Per Persson, CEO, e-mail: per.persson@acarix.com, tel: +46 736 005 990

Christian Lindholm, CFO, e-mail: christian.lindholm@acarix.com, tel: +46 705 118 333

Certified Adviser

Wildecos Ekonomisk Information AB (+46 8 545 271 00, info@wildeco.se) is the Company's Certified Adviser.

About Acarix

Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix's CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readings are obtained in approximately ten minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. See more at www.acarix.com.